Taken together, Nrg4 performed better for predicting various metabolic disorders when compared to other well-recognized molecules that serve as feasible biomarkers, such as adiponectin, homocysteine, and 25-hydroxy vitamin D. These outcomes emphasize that Nrg4 could be a potential biomarker for the occurrence of obesity-related metabolic diseases, but also highlighted the association between low Nrg4 levels and worse visual outcomes and risk of concurrent MetS. This evidence concerns the gene NRG4 and Other metabolic disease.